| EVPM ICSR(s)                       | dividual Case Safety        | EudraVigilance          |  |                   |                          |  |  |  |
|------------------------------------|-----------------------------|-------------------------|--|-------------------|--------------------------|--|--|--|
| General Information                |                             |                         |  |                   |                          |  |  |  |
| EudraVigilance Local Report Number | EU-EC-10011110840           |                         |  |                   |                          |  |  |  |
| Sender Type                        | Health professional         |                         |  |                   |                          |  |  |  |
| Sender's Organisation              | PFIZER S.R.L.               |                         |  |                   |                          |  |  |  |
| Type of Report                     | Spontaneous                 |                         |  |                   |                          |  |  |  |
| Primary source country             | Non-European Economic Area  |                         |  |                   |                          |  |  |  |
| Reporter's qualification           | Healthcare Professional     |                         |  |                   |                          |  |  |  |
| Case serious?                      | Yes                         |                         |  |                   |                          |  |  |  |
| Patient                            |                             |                         |  |                   |                          |  |  |  |
| Age Group                          | Age Group (as per reporter) |                         |  |                   |                          |  |  |  |
| 12-17 Years                        | St. F. Copy Copy Copy       |                         |  |                   | Female                   |  |  |  |
| Reaction / Event                   |                             |                         |  |                   |                          |  |  |  |
| MedDRA LLT                         | Duration                    | Outcome                 |  |                   | Seriousness <sup>1</sup> |  |  |  |
| Oxygen saturation immeasurable     |                             | Fatal                   |  |                   | death., hospital.        |  |  |  |
| Postictal state                    |                             | Fatal                   |  |                   | death., hospital.        |  |  |  |
| Breathing difficult                |                             | Fatal                   |  |                   | death., hospital.        |  |  |  |
| Cyanosis                           |                             | Fatal                   |  |                   | death., hospital.        |  |  |  |
| Chest discomfort                   |                             | Fatal                   |  |                   | death., hospital.        |  |  |  |
| Jugular vein distension            |                             | Fatal                   |  |                   | death., hospital.        |  |  |  |
| Crepitations                       |                             | Fatal                   |  |                   | death., hospital.        |  |  |  |
| Bladder sphincter atony            |                             | Fatal                   |  |                   | death., hospital.        |  |  |  |
| Nervous system disorder            |                             | Fatal                   |  |                   | death., hospital.        |  |  |  |
| Involuntary movement (NOS)         |                             | Fatal                   |  |                   | death., hospital.        |  |  |  |
| Ventricular fibrillation           |                             | Fatal                   |  |                   | death., hospital.        |  |  |  |
| Syncope                            |                             | Fatal                   |  |                   | death., hospital.        |  |  |  |
| Unequal pupils                     |                             | Fatal                   |  |                   | death., hospital.        |  |  |  |
| Bradycardia                        |                             | Fatal                   |  |                   | death., hospital.        |  |  |  |
| Heart arrest                       |                             | Fatal                   |  |                   | death., hospital.        |  |  |  |
| Anal sphincter tone decreased      |                             | Fatal                   |  |                   | death., hospital.        |  |  |  |
| Cyanosis peripheral                |                             | Fatal                   |  |                   | death., hospital.        |  |  |  |
| Afebrile seizure                   |                             | Fatal death., hospital. |  |                   |                          |  |  |  |
| Drug Information                   |                             |                         |  |                   |                          |  |  |  |
| Role <sup>2</sup> Drug             | Duration                    | Dose Units in Interval  |  | Inits in Interval | Action taken             |  |  |  |
| S TOZINAMERAN - TOZINAMERAN        | 1.0 Days                    | Total                   |  | Total             | Not applicable           |  |  |  |
| Drug Information (cont.)           |                             |                         |  |                   |                          |  |  |  |
| Info³ Drug                         | Indication                  | Indication Pharm. For   |  | arm. Form         | Route of Admin.          |  |  |  |

COVID-19 immunisation

TOZINAMERAN - TOZINAMERAN

Intramuscular use

Seriousness: death=results in death; life threat.=life threatening; hospital.=requires hospitalization/prolongation of hospitalization; disability=results in disability/incapacity; congen.=congenital anomaly/birth defect; other=other medically important information; (blank)=non-serious

<sup>2</sup> Drug role: S=suspect; C=concomitant; I=interacting; N=not administered

Additional Information on Drug: 1=Counterfeit; 2= Overdose; 3=Drug taken by the father; 4=Drug taken beyond expiry date; 5=Batch and lot tested and found within specifications; 6=Batch and lot tested and found not within specifications; 7=Medication error; 8=Misuse; 9=Abuse; 10=Occupational exposure; 11=Off label use; (blank) = no additional information